Lipid trafficking in cardiovascular disease

Area of Science:

• Cardiovascular Science
• Lipid Metabolism
• Molecular Biology

Background:

• Cardiovascular disease (CVD) remains a leading cause of mortality worldwide.
• Reducing plasma apolipoprotein B (apoB) lipoproteins is a primary strategy for CVD risk reduction.
• Despite progress, new therapeutic targets are needed due to persistent CVD morbidity and mortality.

Purpose of the Study:

• To review the role of lipid trafficking in atherosclerosis.
• To assess molecular mechanisms underlying atherogenic lipid changes.
• To discuss new developments in CVD risk assessment and residual risk mitigation.

Main Methods:

• Literature review of clinical and preclinical research.
• Analysis of molecular mechanisms of lipid transport.
• Evaluation of emerging risk assessment tools and therapeutic targets.

Main Results:

• Lipid trafficking mechanisms are crucial in CVD pathogenesis, beyond simple lipid accumulation/removal.
• Atherogenic changes in lipid movement contribute significantly to CVD.
• New insights into lipid orchestration offer novel therapeutic avenues.

Conclusions:

• Understanding lipid trafficking is key to developing new CVD therapies.
• Targeting molecular mechanisms of lipid movement can mitigate residual CVD risk.
• Further research into lipid orchestration and risk assessment is warranted.